Cargando…

The Potential Contribution of Dental Foci and Oral Mucositis to Febrile Neutropenia in Patients Treated With Myelosuppressive Chemotherapy for Solid Tumors and Lymphoma

INTRODUCTION: Febrile neutropenia (FN) is a potential life-threatening complication of myelosuppressive chemotherapy, particularly when induced by infection. There is evidence that FN can originate from the oral cavity, but its contribution to FN is largely understudied in patients treated for solid...

Descripción completa

Detalles Bibliográficos
Autores principales: Zecha, Judith A. E. M., Raber-Durlacher, Judith E., Laheij, Alexa M. G. A., Westermann, Anneke M., de Lange, Jan, Smeele, Ludi E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280026/
https://www.ncbi.nlm.nih.gov/pubmed/35846111
http://dx.doi.org/10.3389/froh.2022.940044
_version_ 1784746541582385152
author Zecha, Judith A. E. M.
Raber-Durlacher, Judith E.
Laheij, Alexa M. G. A.
Westermann, Anneke M.
de Lange, Jan
Smeele, Ludi E.
author_facet Zecha, Judith A. E. M.
Raber-Durlacher, Judith E.
Laheij, Alexa M. G. A.
Westermann, Anneke M.
de Lange, Jan
Smeele, Ludi E.
author_sort Zecha, Judith A. E. M.
collection PubMed
description INTRODUCTION: Febrile neutropenia (FN) is a potential life-threatening complication of myelosuppressive chemotherapy, particularly when induced by infection. There is evidence that FN can originate from the oral cavity, but its contribution to FN is largely understudied in patients treated for solid tumors. The aim of this study was to assess the prevalence of FN in these patients and to evaluate its relation with dental foci and oral mucositis. MATERIAL AND METHODS: A prospective longitudinal observational study was conducted. Patients diagnosed with solid tumors and lymphoma scheduled to be treated with myelosuppressive chemotherapy with an intermediate risk of developing FN were included. A pre-chemotherapy dental examination was performed and patients were followed during and after chemotherapy regimen. During subsequent hospital visits for chemotherapy administration, the oral cavity was inspected and oral mucositis (OM) was scored using the CTC-AE version 3.0. When patients presented with fever, a comprehensive full body examination including laboratory/microbiological/imaging investigation was performed. RESULTS: Eighty-eight patients were included. Pre-chemotherapy, 39 patients (44.3%) were diagnosed with a dental focus. During chemotherapy, 46 patients developed OM (53.4%), of which 15 patients had a maximum score of grade II (ulcerative mucositis). Ten patients developed FN during the follow-up period. Patients with FN more often suffered from ulcerative OM compared to patients without FN; both FN and mucositis risk was associated with the myelotoxicity of chemotherapy. However, no relation could be established between the presence of dental foci prior to chemotherapy and the development of FN (p > 0.05). CONCLUSION: A significant relation was identified between ulcerative OM and FN, but no robust conclusions could be drawn with respect to a relationship between the presence of dental foci and FN.
format Online
Article
Text
id pubmed-9280026
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92800262022-07-15 The Potential Contribution of Dental Foci and Oral Mucositis to Febrile Neutropenia in Patients Treated With Myelosuppressive Chemotherapy for Solid Tumors and Lymphoma Zecha, Judith A. E. M. Raber-Durlacher, Judith E. Laheij, Alexa M. G. A. Westermann, Anneke M. de Lange, Jan Smeele, Ludi E. Front Oral Health Oral Health INTRODUCTION: Febrile neutropenia (FN) is a potential life-threatening complication of myelosuppressive chemotherapy, particularly when induced by infection. There is evidence that FN can originate from the oral cavity, but its contribution to FN is largely understudied in patients treated for solid tumors. The aim of this study was to assess the prevalence of FN in these patients and to evaluate its relation with dental foci and oral mucositis. MATERIAL AND METHODS: A prospective longitudinal observational study was conducted. Patients diagnosed with solid tumors and lymphoma scheduled to be treated with myelosuppressive chemotherapy with an intermediate risk of developing FN were included. A pre-chemotherapy dental examination was performed and patients were followed during and after chemotherapy regimen. During subsequent hospital visits for chemotherapy administration, the oral cavity was inspected and oral mucositis (OM) was scored using the CTC-AE version 3.0. When patients presented with fever, a comprehensive full body examination including laboratory/microbiological/imaging investigation was performed. RESULTS: Eighty-eight patients were included. Pre-chemotherapy, 39 patients (44.3%) were diagnosed with a dental focus. During chemotherapy, 46 patients developed OM (53.4%), of which 15 patients had a maximum score of grade II (ulcerative mucositis). Ten patients developed FN during the follow-up period. Patients with FN more often suffered from ulcerative OM compared to patients without FN; both FN and mucositis risk was associated with the myelotoxicity of chemotherapy. However, no relation could be established between the presence of dental foci prior to chemotherapy and the development of FN (p > 0.05). CONCLUSION: A significant relation was identified between ulcerative OM and FN, but no robust conclusions could be drawn with respect to a relationship between the presence of dental foci and FN. Frontiers Media S.A. 2022-06-30 /pmc/articles/PMC9280026/ /pubmed/35846111 http://dx.doi.org/10.3389/froh.2022.940044 Text en Copyright © 2022 Zecha, Raber-Durlacher, Laheij, Westermann, de Lange and Smeele. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oral Health
Zecha, Judith A. E. M.
Raber-Durlacher, Judith E.
Laheij, Alexa M. G. A.
Westermann, Anneke M.
de Lange, Jan
Smeele, Ludi E.
The Potential Contribution of Dental Foci and Oral Mucositis to Febrile Neutropenia in Patients Treated With Myelosuppressive Chemotherapy for Solid Tumors and Lymphoma
title The Potential Contribution of Dental Foci and Oral Mucositis to Febrile Neutropenia in Patients Treated With Myelosuppressive Chemotherapy for Solid Tumors and Lymphoma
title_full The Potential Contribution of Dental Foci and Oral Mucositis to Febrile Neutropenia in Patients Treated With Myelosuppressive Chemotherapy for Solid Tumors and Lymphoma
title_fullStr The Potential Contribution of Dental Foci and Oral Mucositis to Febrile Neutropenia in Patients Treated With Myelosuppressive Chemotherapy for Solid Tumors and Lymphoma
title_full_unstemmed The Potential Contribution of Dental Foci and Oral Mucositis to Febrile Neutropenia in Patients Treated With Myelosuppressive Chemotherapy for Solid Tumors and Lymphoma
title_short The Potential Contribution of Dental Foci and Oral Mucositis to Febrile Neutropenia in Patients Treated With Myelosuppressive Chemotherapy for Solid Tumors and Lymphoma
title_sort potential contribution of dental foci and oral mucositis to febrile neutropenia in patients treated with myelosuppressive chemotherapy for solid tumors and lymphoma
topic Oral Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280026/
https://www.ncbi.nlm.nih.gov/pubmed/35846111
http://dx.doi.org/10.3389/froh.2022.940044
work_keys_str_mv AT zechajudithaem thepotentialcontributionofdentalfociandoralmucositistofebrileneutropeniainpatientstreatedwithmyelosuppressivechemotherapyforsolidtumorsandlymphoma
AT raberdurlacherjudithe thepotentialcontributionofdentalfociandoralmucositistofebrileneutropeniainpatientstreatedwithmyelosuppressivechemotherapyforsolidtumorsandlymphoma
AT laheijalexamga thepotentialcontributionofdentalfociandoralmucositistofebrileneutropeniainpatientstreatedwithmyelosuppressivechemotherapyforsolidtumorsandlymphoma
AT westermannannekem thepotentialcontributionofdentalfociandoralmucositistofebrileneutropeniainpatientstreatedwithmyelosuppressivechemotherapyforsolidtumorsandlymphoma
AT delangejan thepotentialcontributionofdentalfociandoralmucositistofebrileneutropeniainpatientstreatedwithmyelosuppressivechemotherapyforsolidtumorsandlymphoma
AT smeeleludie thepotentialcontributionofdentalfociandoralmucositistofebrileneutropeniainpatientstreatedwithmyelosuppressivechemotherapyforsolidtumorsandlymphoma
AT zechajudithaem potentialcontributionofdentalfociandoralmucositistofebrileneutropeniainpatientstreatedwithmyelosuppressivechemotherapyforsolidtumorsandlymphoma
AT raberdurlacherjudithe potentialcontributionofdentalfociandoralmucositistofebrileneutropeniainpatientstreatedwithmyelosuppressivechemotherapyforsolidtumorsandlymphoma
AT laheijalexamga potentialcontributionofdentalfociandoralmucositistofebrileneutropeniainpatientstreatedwithmyelosuppressivechemotherapyforsolidtumorsandlymphoma
AT westermannannekem potentialcontributionofdentalfociandoralmucositistofebrileneutropeniainpatientstreatedwithmyelosuppressivechemotherapyforsolidtumorsandlymphoma
AT delangejan potentialcontributionofdentalfociandoralmucositistofebrileneutropeniainpatientstreatedwithmyelosuppressivechemotherapyforsolidtumorsandlymphoma
AT smeeleludie potentialcontributionofdentalfociandoralmucositistofebrileneutropeniainpatientstreatedwithmyelosuppressivechemotherapyforsolidtumorsandlymphoma